Spruce Biosciences Stock News

Spruce Biosciences Inc. (NASDAQ:SPRB) traded at $3.95 at last check on Tuesday, December 21, made a downward move of -7.38% on its previous days price. Looking at the stock we see that its previous close was $4.27 with the days price range being $3.53 $4.36. In terms of its 52-week price range, SPRB has Investors Take Advantage Of -7.38% Loss In Spruce Biosciences Inc. (NASDAQ: SPRB) Read More »

5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?

NEW YORK , Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRLD, MNSO, GRTX, SPRB, and PRPL. Full story available on Benzinga.com

The stock price of Spruce Biosciences Inc (NASDAQ: SPRB) increased by 102.82% in the previous trading session. This is why it happened.

Stocks, Yields Tumble As Quad-Witching Fears Add To Broader Market Slide US futures tumbled after hitting an all time high less than 24 hour ago, as the favorable if paradoxical bounce in risk from the hawkish FOMC pivot faded from memory and as investors questioned whether global stocks are due for a rough ride on the backdrop of growing risks from inflation and the omicron virus variant. S&P 500 futures slumped about 0.5% Friday morning, while the U.S. 10-year Treasury yield fell for a second straight day to 1.394%, the lowest since Dec. 6. Futures were dragged down by tech stocks as volatility surged amid mounting concerns about monetary tightening and the omicron coronavirus variant. Rates hikes do not end bull markets, but reversal of central banks liquidity means less speculative froth and more volatility, said Barclays strategist Emmanuel Cau. Policy angst may be here to stay, but following months of unclear guidances and conflicting signals, the direction of travel is clear now. Investors are also bracing for the quarterly rebalancing of the S&P 500 Index after the market close and the triple witching expiration of equity derivatives that could magnify market moves.

Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agree

Zacks Investment Research upgraded shares of Spruce Biosciences (NASDAQ:SPRB) from a hold rating to a buy rating in a research note published on Monday morning, Zacks.com reports. Zacks Investment Research currently has $3.00 price objective on the stock. According to Zacks, Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel []

Spruce Biosciences (NASDAQ:SPRB) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Monday, Zacks.com reports. The brokerage currently has a $3.00 price target on the stock. Zacks Investment Researchs target price would indicate a potential upside of 16.28% from the companys previous close. According []

Cowen cut shares of Spruce Biosciences (NASDAQ:SPRB) from an outperform rating to a market perform rating in a report released on Tuesday morning, PriceTargets.com reports. A number of other brokerages also recently commented on SPRB. Zacks Investment Research raised shares of Spruce Biosciences from a sell rating to a hold rating in a research report []

Spruce Biosciences Inc. (NASDAQ:SPRB) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 5.66% to the previous days close as strong demand from buyers drove the stock to $2.80. Actively observing the price movement in the last trading, the stock closed the session at $2.65, falling within a range of $2.66 Read This First Before You Buy Spruce Biosciences Inc. (NASDAQ: SPRB) Stock Read More »

Spruce Biosciences (NASDAQ:SPRB) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an []

Zacks Investment Research upgraded shares of Spruce Biosciences (NASDAQ:SPRB) from a sell rating to a hold rating in a report released on Friday morning, Zacks.com reports. According to Zacks, Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy []

Spruce Biosciences (NASDAQ:SPRB) had its price target trimmed by HC Wainwright from $30.00 to $20.00 in a research note published on Tuesday, The Fly reports. The firm currently has a buy rating on the stock. A number of other analysts have also recently commented on the company. SVB Leerink cut Spruce Biosciences from an outperform []

Spruce Biosciences (NASDAQ:SPRB) had its price objective lowered by Credit Suisse Group from $26.00 to $6.00 in a research note released on Tuesday, The Fly reports. The brokerage currently has an outperform rating on the stock. Several other equities research analysts have also issued reports on SPRB. Zacks Investment Research lowered Spruce Biosciences from a []

Spruce Biosciences (NASDAQ:SPRB) announced its quarterly earnings results on Sunday. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts consensus estimates of ($0.57) by $0.08, MarketWatch Earnings reports. SPRB stock traded down $0.84 during trading on Tuesday, reaching $3.55. The companys stock had a trading volume of 2,439 shares, compared to []